Cargando…

Ruthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment

Colorectal cancer (CRC) is one of the intimidating causes of death around the world. CRC originated from mutations of tumor suppressor genes, proto-oncogenes and DNA repair genes. Though platinum (Pt)-based anticancer drugs have been widely used in the treatment of cancer, their toxicity and CRC cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahmud, Kazi Mustafa, Niloy, Mahruba Sultana, Shakil, Md Salman, Islam, Md Asiful
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398452/
https://www.ncbi.nlm.nih.gov/pubmed/34452256
http://dx.doi.org/10.3390/pharmaceutics13081295
_version_ 1783744843555536896
author Mahmud, Kazi Mustafa
Niloy, Mahruba Sultana
Shakil, Md Salman
Islam, Md Asiful
author_facet Mahmud, Kazi Mustafa
Niloy, Mahruba Sultana
Shakil, Md Salman
Islam, Md Asiful
author_sort Mahmud, Kazi Mustafa
collection PubMed
description Colorectal cancer (CRC) is one of the intimidating causes of death around the world. CRC originated from mutations of tumor suppressor genes, proto-oncogenes and DNA repair genes. Though platinum (Pt)-based anticancer drugs have been widely used in the treatment of cancer, their toxicity and CRC cells’ resistance to Pt drugs has piqued interest in the search for alternative metal-based drugs. Ruthenium (Ru)-based compounds displayed promising anticancer activity due to their unique chemical properties. Ru-complexes are reported to exert their anticancer activities in CRC cells by regulating different cell signaling pathways that are either directly or indirectly associated with cell growth, division, proliferation, and migration. Additionally, some Ru-based drug candidates showed higher potency compared to commercially available Pt-based anticancer drugs in CRC cell line models. Meanwhile Ru nanoparticles coupled with photosensitizers or anticancer agents have also shown theranostic potential towards CRC. Ru-nanoformulations improve drug efficacy, targeted drug delivery, immune activation, and biocompatibility, and therefore may be capable of overcoming some of the existing chemotherapeutic limitations. Among the potential Ru-based compounds, only Ru (III)-based drug NKP-1339 has undergone phase-Ib clinical trials in CRC treatment.
format Online
Article
Text
id pubmed-8398452
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83984522021-08-29 Ruthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment Mahmud, Kazi Mustafa Niloy, Mahruba Sultana Shakil, Md Salman Islam, Md Asiful Pharmaceutics Review Colorectal cancer (CRC) is one of the intimidating causes of death around the world. CRC originated from mutations of tumor suppressor genes, proto-oncogenes and DNA repair genes. Though platinum (Pt)-based anticancer drugs have been widely used in the treatment of cancer, their toxicity and CRC cells’ resistance to Pt drugs has piqued interest in the search for alternative metal-based drugs. Ruthenium (Ru)-based compounds displayed promising anticancer activity due to their unique chemical properties. Ru-complexes are reported to exert their anticancer activities in CRC cells by regulating different cell signaling pathways that are either directly or indirectly associated with cell growth, division, proliferation, and migration. Additionally, some Ru-based drug candidates showed higher potency compared to commercially available Pt-based anticancer drugs in CRC cell line models. Meanwhile Ru nanoparticles coupled with photosensitizers or anticancer agents have also shown theranostic potential towards CRC. Ru-nanoformulations improve drug efficacy, targeted drug delivery, immune activation, and biocompatibility, and therefore may be capable of overcoming some of the existing chemotherapeutic limitations. Among the potential Ru-based compounds, only Ru (III)-based drug NKP-1339 has undergone phase-Ib clinical trials in CRC treatment. MDPI 2021-08-19 /pmc/articles/PMC8398452/ /pubmed/34452256 http://dx.doi.org/10.3390/pharmaceutics13081295 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mahmud, Kazi Mustafa
Niloy, Mahruba Sultana
Shakil, Md Salman
Islam, Md Asiful
Ruthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment
title Ruthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment
title_full Ruthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment
title_fullStr Ruthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment
title_full_unstemmed Ruthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment
title_short Ruthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment
title_sort ruthenium complexes: an alternative to platinum drugs in colorectal cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8398452/
https://www.ncbi.nlm.nih.gov/pubmed/34452256
http://dx.doi.org/10.3390/pharmaceutics13081295
work_keys_str_mv AT mahmudkazimustafa rutheniumcomplexesanalternativetoplatinumdrugsincolorectalcancertreatment
AT niloymahrubasultana rutheniumcomplexesanalternativetoplatinumdrugsincolorectalcancertreatment
AT shakilmdsalman rutheniumcomplexesanalternativetoplatinumdrugsincolorectalcancertreatment
AT islammdasiful rutheniumcomplexesanalternativetoplatinumdrugsincolorectalcancertreatment